| Expression pattern: |
UP |
| Associated gene: |
ERBB4, Ago2 |
| Associated microRNA: |
miR-505-3p |
| Biological function: |
Promotes NSCLC tumorigenesis, proliferation, migration, DDP resistance and cell survival; inhibits apoptosis and DDP sensitivity. |
| Molecular mechanism: |
circGCLM functions as a ceRNA by sponging miR-505-3p, thereby derepressing ERBB4 expression and mediating DDP resistance and malignant phenotypes. |
| Biological pathway or process: |
ceRNA regulation (promotes); drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); migration (promotes); apoptosis (inhibits); ERK (promotes); PI3K/AKT (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Wound Healing Assay; Transwell Assay; TUNEL; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
Potential therapeutic target for overcoming chemoresistance. |
| Description: |
circGCLM (hsa_circ_0003513), derived from the GCLM gene, is upregulated in DDP-resistant NSCLC cells. It promotes proliferation, migration, tumor growth and cisplatin resistance while suppressing apoptosis, mainly through a ceRNA mechanism in which circGCLM sponges miR-505-3p to derepress ERBB4. Knockdown of circGCLM sensitizes resistant NSCLC cells and xenografts to DDP, suggesting therapeutic relevance for chemoresistant NSCLC. |
| Confidence score: |
0.8 |